Psychedelic Virtual Reality

March 24, 2026 updated by: Anahita Bassir Nia, Yale University

Investigating the Use of Virtual Reality in Psychedelic Research or Clinical Practice

The purpose of this study is to evaluate a novel VRP.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The primary objective of this study is to determine whether the subjective experience of a novel VRP (DeepDream) will be comparable to a standard dose of psychedelics. This study also looks to compare the subjective experience of DeepDream VRP to other available VR modalities developed to mimic psychedelic subjective experience along with assessing the incidence of VRP adverse effects.

Study Type

Observational

Enrollment (Actual)

10

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Connecticut
      • New Haven, Connecticut, United States, 06510
        • Yale University School Of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Healthy volunteers

Description

Inclusion Criteria:

  • Ability to provide informed consent
  • No history or current DSM-V diagnosis

Exclusion Criteria:

  • Unstable medical conditions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Healthy Volunteer
Device: Meta Quest 3
Meta Quest 3 is a virtual reality headset device

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
Time Frame: Day 0 through Day 30
Subject experience will be assessed using the Altered States of Consciousness Rating Scale.
Day 0 through Day 30
Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
Time Frame: Day 0 through Day 30
Subject experience will be assessed using the Mystical Experience Questionnaire.
Day 0 through Day 30
Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.
Time Frame: Day 0 through Day 30
Subject experience will be assessed using the Ego-Dissolution Inventory.
Day 0 through Day 30

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assess the incidence of VRP adverse effects, principally virtual reality sickness (VRS) and neck and upper back pain.
Time Frame: Day 0 through Day 30
The number of adverse events will be assessed through qualitative interviews following VRP viewing.
Day 0 through Day 30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yale University

Investigators

  • Principal Investigator: Anahita Bassir Nia, MD, Yale University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 22, 2025

Primary Completion (Actual)

March 22, 2026

Study Completion (Actual)

March 22, 2026

Study Registration Dates

First Submitted

August 27, 2024

First Submitted That Met QC Criteria

August 29, 2024

First Posted (Actual)

September 3, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2026

Last Update Submitted That Met QC Criteria

March 24, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2000038121

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Volunteer

Clinical Trials on Meta Quest 3

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe